Objectives: To assess simplified maintenance regimens containing dual antiretroviral drugs in patients with controlled human immunodeficiency virus type 1 infection.
Introduction
The combination of two nucleoside analogues plus a protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) is the currently recommended treatment for human immunodeficiency virus type 1 (HIV-1) infection. This highly active antiretroviral therapy (HAART) rapidly reduces viral burden in plasma, lymphatic tissue and CSF. 1 However, HAART can yield severe toxic effects such as lipodystrophy, dyslipidaemia and lactic acidosis.
2, 3 Moreover, before once-daily antiretroviral drugs were available, long-term adherence would have been difficult to achieve due to the number of pills and the complexity of dosing schedules. Indeed, adherence is critical to achieve persistent suppression of HIV replication, which is in turn a requirement for the prevention of viral drug resistance. 4 Therefore, attempts were made at the end of the 1990s to introduce a simplified maintenance regimen after an initial aggressive induction phase with triple or quadruple therapy. The aim of maintenance therapy was to keep the viral load below the limit of detection while limiting HAART toxicity. Three large trials were set up to answer this question: ADAM, ACTG 343 and ANRS 072-TRILEGE. 5 -7 These clinical studies published in 1998 suggested that antiretroviral strategies with successive induction and maintenance sequences could not be used in general practice. With the development of the NNRTI efavirenz and the nucleotide analogue tenofovir disoproxil fumarate (tenofovir DF), new treatment strategies emerged. Although the initial phase of antiretroviral treatment (i.e. the first 6 -12 months) requires hitting the virus hard, well-controlled patients, particularly those on potent drugs, may still control their infection with fewer drugs. Moreover, switching from PI-containing HAART to a PI-sparing regimen was demonstrated to reduce the risk of lipodystrophy and treatment discontinuation. 8 Based on published data showing the potent antiretroviral effect of tenofovir DF, we hypothesized that a two-drug therapy with tenofovir DF and efavirenz should be both efficacious and well tolerated allowing, in case of virological failure, the possibility of a standardized salvage therapy [i.e. a PI with alternative nucleoside reverse transcriptase inhibitors (NRTIs) without cross-resistance to tenofovir DF]. Therefore, this trial was designed to evaluate this innovative strategy versus recommended triple-drug antiretroviral regimen.
Patients and methods

Study population and design
This study was a multicentre, randomized, open-label trial of maintenance therapy conducted in 24 AIDS clinical centres in France (COOL trial). Patients were randomized (1:1) to receive either a once-daily maintenance regimen of a two-drug combination (tenofovir DF and efavirenz) or a conventional three-drug combination (tenofovir DF, lamivudine and efavirenz) in virologically controlled HIV-1 patients.
Adult patients with documented HIV-1 infection were eligible if they had no clinical and/or biological signs of acute opportunistic infection or primary HIV-1 infection, weight 45 kg, stable HAART (no change in the previous 3 months) containing at least three drugs, a plasma viral load of ,50 copies/mL for at least 6 months (no confirmed transitory elevations-straddled by a viral load ,50 copies/mL before and after the elevation-or 'blips' up to 1000 copies/mL were acceptable), no previous single or dual antiretroviral therapy, no previous virological failure and no previous tenofovir DF treatment ( previous efavirenz treatment was allowed). Main criteria for non-inclusion were history of severe renal disorder (creatininaemia at inclusion should be ,133 mmol/L or creatinine clearance .60 mL/min), ongoing serious disease, severe hepatic disease, known hypersensitivity to any component of study medications and childbearing or pregnant women.
Written informed consent was obtained from each patient. The protocol was conducted in accordance with the Declaration of Helsinki and French law for biomedical research, and was approved by the Ethics Committee of Saint-Antoine Hospital (Paris, France).
Patients randomized into the two-drug group received 300 mg of tenofovir DF and 600 mg of efavirenz, and those randomized into the three-drug group received 300 mg of tenofovir DF, 300 mg of lamivudine and 600 mg of efavirenz. All study drugs were given once daily. The allocation of patients to treatment groups was centralized using block randomized assignment. If patients experienced neurological adverse events (AEs) related to efavirenz, nevirapine could be substituted.
Patients were followed up at weeks 4, 12, 24, 36 and 48 for clinical examination, AE assessments and biochemical and biological tests (including CD4/CD8 cells counts, HIV-1 RNA determination and metabolic/morphologic profile). The quantification of plasma HIV-1 RNA was performed using a technique with a cut-off of 50 copies/mL. Two different techniques were used at each centre according to current practice: Roche Amplicor HIV-1 Monitor w test (version 1.5; Roche Diagnostic Systems, Inc., Branchburg, NJ, USA) or Quantiplex HIV-1 RNA w assay (Chiron Diagnostics, Emeryville, CA, USA). When HIV-1 RNA was .50 copies/mL, a new sample was obtained 2 weeks later. Virological failure was defined as plasma HIV-1 RNA .50 copies/mL, confirmed on two consecutive measurements. HIV-1 was also quantified on baseline and week 48 samples of the biobank at a central laboratory using Cobas AmpliPrep-Cobas Taqman HIV-1 w (Roche Diagnostic Systems). For patients with virological failure, the sequence of the reverse transcriptase and protease was determined at the time of failure and a posteriori on baseline DNA samples.
Measurement of abdominal adipose compartments was performed by computed tomography (CT) scan centred on L4 at baseline and week 48. 9 Quantifications of soft tissues (adipose tissue and lean mass) and bone mineral density were assessed by LUNAR dual-energy X-ray absorptiometry (DEXA) at baseline and week 48 in a subgroup of patients (DEXA scan was available in only three centres). Quality of life was evaluated at baseline and weeks 24 and 48 using the Medical Outcomes Short Form (SF-36). Treatment compliance for the 4 previous days was evaluated by a selfquestionnaire on treatment.
The primary endpoint was the proportion of patients with plasma HIV-1 RNA ,50 copies/mL at week 48 in the absence of treatment modification. Patients with missing data for the primary endpoint were considered as treatment failures in the intention-to-treat (ITT) analysis.
Statistical analysis
With a non-inferiority margin set at 14%, and a proportion of success at 90%, it was calculated that 70 subjects per treatment group would be needed to show non-inferiority (a one-sided, 5%; power, 85%) of the two-drug group. The ITT and safety populations included randomized patients who received at least one dose of trial treatment. The per protocol (PP or as treated) population included Two-drug versus three-drug maintenance regimens patients who received at least one dose of trial treatment, with at least one evaluation at baseline and after baseline and with no major deviation from the protocol.
The difference in the proportions of success (as defined by the protocol) between treatment groups was calculated and its confidence interval (CI) was estimated according to the binomial law. The hypothesis of non-inferiority of the two treatment groups was tested by comparing the upper limit of the one-sided 95% CI of the difference of proportion between groups to the margin set at 14%.
Results
Disposition of patients and baseline characteristics
From March 2003 to May 2005, 148 patients were randomized into the trial (Figure 1 ). Among them, 143 received at least one dose of trial treatment and were considered in the ITT and safety populations: 72 patients in the three-drug group and 71 patients in the two-drug group.
Baseline demographic and laboratory characteristics were balanced between the treatment groups ( Table 1) . About one-third of the patients were already at the AIDS stage and patients had received HAART for a median of 4 years (84% with a three-drug combination and 16% with a four-drug combination). At inclusion, patients received two NRTIs associated with either a PI (49%) or an NNRTI (45%). The most frequent NRTI backbone was zidovudine plus lamivudine (71.3%). All patients had HIV-1 RNA ,50 copies/mL except six: one in the three-drug group (64 copies/mL) and five in the two-drug group (54, 85, 131, 735 and 1690 copies/mL). Median CD4 cell count was 473 cells/mm 3 . Lipid-lowering treatments (fibrates or statins) were received by 4.9% of all patients without difference between treatment groups.
The PP population included 130 patients who did not experience major protocol deviations: 70 patients in the three-drug group and 60 patients in the two-drug group. Main major protocol deviations determined during blind review of data were inclusion/exclusion criteria not met, study medication dispensing error, treatment discontinuation without valid justification or missing data.
During the 48 weeks of the trial, two patients permanently discontinued the treatment regimen in the three-drug group (n ¼ 72, 2.8%) and 13 in the two-drug group (n¼ 71, 18.3%). The main reasons for treatment discontinuation are depicted in Figure 1 .
Virological analysis
In the ITT population, 81.7% of patients in the two-drug group (95% CI, 70.7% -89.9%) maintained HIV-1 RNA ,50 copies/mL at week 48 without treatment change, compared with 97.2% (95% CI, 90.3% -99.7%) in the three-drug group (Table 2) , yielding a difference of 15.5% (upper limit of onesided 95% CI, 23.7%). In the PP population, the proportion of patients meeting the primary endpoint in the two-drug and threedrug groups was 90% and 100%, respectively, yielding a b DEXA measurements at baseline were performed in a limited number of centres (n¼23 patients in the three-drug group and n¼19 in the two-drug group). c CT scan measurements at baseline are reported for patients of the ITT population with available data (n ¼56 in the three-drug group and n¼55 in the two-drug group). Consequently, non-inferiority was not achieved for the two-drug regimen of tenofovir DF plus efavirenz compared with the threedrug regimen of tenofovir, lamivudine and efavirenz. The number of patients displaying viral load blips (defined as a measurement of plasma HIV-1 RNA between 50 and 1000 copies/mL followed by a measurement of ,50 copies/mL 2 weeks later) from week 4 to week 48 was nine and three in the three-drug and two-drug groups, respectively.
The reasons for failure in the ITT population are described in Table 3 . Three patients (4.2%) in the two-drug group and no patients in the three-drug group experienced virological failure. NNRTI mutations were detected in all patients experiencing virological failure. The first patient had the Y188L mutation identified at week 24 (HIV RNA was 1490 copies/mL, which returned to ,50 copies/mL after treatment with zidovudine/lamivudine/indinavir/ritonavir). For the second patient, the K101E, K103R and G190A mutations were identified at week 25 (the mutation K103R was already present at baseline as evidenced a posteriori on baseline DNA samples; HIV RNA was 257720 copies/mL at week 25 and returned to ,50 copies/mL after treatment with zidovudine/lamivudine/atazanavir). The third patient had the G190E mutation identified at the last visit at week 48 (HIV RNA, 1600 copies/mL); after 6 months, viral load was 648 copies/mL without treatment modification. Other reasons for treatment failure (according to the protocol) in the ITT population were study drug regimen discontinuation due to unrelated (one patient in the two-drug group) or related (three patients in the two-drug group) AEs, lost to follow-up or patient request for study discontinuation (two patients in the three-drug group and six patients in the two-drug group).
Statistically significantly, more patients demonstrated a treatment compliance of 80% in the three-drug group (48/49, 98%) compared with the two-drug group (32/38, 84%) (P ¼ 0.04).
Immunological changes
Overall, CD4 counts showed a statistically significant increase during the study: from 473 cells/mm 3 
Safety
Median duration of exposure was 336 days for both treatment groups. Sixty-one patients (84.7%) reported at least one AE in the three-drug group and 62 patients (87.3%) in the two-drug group. AEs led to study drug discontinuation in four patients in the two-drug group and none in the three-drug group.
Serious adverse events (SAEs) were reported for 13 patients: 10 in the two-drug therapy group (10 SAEs, 14%) and 3 in the three-drug group (3 SAEs, 4%; P ¼0.039). Five SAEs in the two-drug group were considered to be possibly related to study treatment: cytolytic hepatitis (n¼ 2), dizziness, depression and psychiatric disorder. Of these SAEs, three led to discontinuation of study treatment: dizziness (n ¼1), suicide attempt (n ¼ 1) and cytolytic hepatitis (n¼ 1).
Overall, no statistically significant median changes from baseline were observed in serum creatinine (0.0 mg/L; IQR, 21.0 to 0.9 mg/L; P ¼ 0.64), serum creatinine clearance (21.3 mL/min; IQR, 211.3 to 8.2; P¼ 0.31) and phosphataemia (0.0 mmol/L; IQR, 20.1 to 0.1; P ¼ 0.98) at week 48. There were statistically significant overall median changes in serum lactic acid concentration (median decrease of 0.14 mmol/L; P ¼ 0.006) and haemoglobin (median increase of 0.60 g/dL; P, 0.0001). No statistically significant differences were observed between the two treatment groups for any of the selected biological parameters.
Lipid and bone metabolism, fat distribution
Median changes in lipid parameters in the overall PP population were analysed between baseline and week 48 (Table 4) . At baseline, lipid parameters were within the normal range. At week 48, statistically significant overall median changes from baseline were observed for triglycerides (20.31 mmol/L; P, 0.0001), total cholesterol (20.25 mmol/L; P ¼ 0.0006) and high-density lipoprotein (HDL) cholesterol (þ0.05 mmol/L; P ¼ 0.041). No statistically significant differences were observed between the two treatment groups for these three lipid parameters. The overall median change from baseline in low-density lipoprotein (LDL) cholesterol was not statistically significant at week 48, although a comparison of the median change between the two treatment groups found it to be statistically significant Patients' median weight did not change significantly during the study: from 68 (IQR, 63-76) kg at baseline to 69 (IQR, 62 -78) kg at week 48 (median change, 0.0 kg; IQR, 22.0 to 3.0 kg; n ¼ 134). CT measurement of abdominal adipose tissue is summarized in Table 5 . CT scan measurements are reported for 80 patients of the PP population with data available both at baseline and week 48 (n ¼ 42 in the three-drug group and n ¼ 38 in the two-drug group). Overall, the surface area of abdominal subcutaneous adipose tissue (SAT) statistically significantly increased between baseline and week 48 (þ9.0 cm 2 ; IQR, 214.1 to 25.9; P ¼ 0.017) without statistically significant differences between treatment groups (median changes were þ11.0 cm 2 in the three-drug group versus þ7.5 cm 2 in the two-drug group; P ¼ 0.70). Surface area of abdominal visceral adipose tissue (VAT) did not statistically significantly change in the overall population (median changes were þ3.4 cm 2 in the three-drug group versus 29.0 cm 2 in the two-drug group; P ¼ 0.85) and there was no statistically significant difference between treatment a DEXA measurements were performed in a limited number of centres and reported for patients of the PP population with data available (n ¼21 patients in the three-drug group and n ¼12 in the two-drug group); CT scan measurements are reported for patients of the PP population with data available (n¼47 in the three-drug group and n¼43 in the two-group). b Wilcoxon rank sum test for two-drug versus three-drug group; Wilcoxon signed rank test for week 48 versus baseline. Changes in bone status and soft tissue composition during the study were assessed using DEXA measurements on a subgroup of patients (n¼ 21 in the three-drug group and n¼ 12 in the two-drug group). As indicated in Table 4 , changes in total fat and lean mass from baseline to week 48 in the overall population were minimal and there were no statistically significant differences between the two treatment groups. A small (20.02), although statistically significant (P ¼ 0.0002), median decrease in bone mineral density was observed from baseline to week 48 with no statistically significant difference observed between treatment groups (P¼ 0.66).
Quality of life
The median total score of the SF-36 questionnaire in the PP population showed a statistically significant increase from 81.3 at baseline to 83.8 at week 48 (P¼ 0.015, Wilcoxon signed rank test; n¼ 103). No difference was observed between the two treatment groups for the total score and subscores of the SF-36 questionnaire.
Discussion
Although the results of induction-maintenance trials performed in the 1990s were disappointing, 5 -7 the increased anti-HIV efficacy of tenofovir DF as compared with previous NRTIs such as zidovudine, didanosine and lamivudine 10 led us to hypothesize that the conventional dual-NRTI backbone component could be replaced by tenofovir DF alone. The choice of efavirenz was prompted by the excellent results obtained in numerous maintenance trials using it as a third agent. 11 -13 Although the toxicity of lamivudine is one of the lowest of the NRTI class, a two-drug maintenance regimen (tenofovir DF plus efavirenz) without lamivudine was designed because of the potential benefits of sparing lamivudine for eventual use in case of failure, its low genetic barrier and cost-sparing. Beyond the sparing of lamivudine from a combined therapy, this trial was a proof of concept study on the two-drug versus three-drug maintenance therapy.
A complete evaluation was performed for efficacy, lipid disorders and other biochemistry parameters as well as safety, quality of life and treatment compliance. As the follow-up was short (48 weeks), we also monitored morphological modifications by sensitive methods such as abdominal CT and DEXA.
Based on both an ITT and a PP analysis, the COOL trial did not demonstrate the non-inferiority of the two-drug regimen of tenofovir DF plus efavirenz compared with the three-drug regimen of tenofovir, lamivudine and efavirenz in the treatment of HIV-1-infected patients. Baseline characteristics of patients were all well balanced. We do not believe that a higher CD4 count in the triple therapy arm may explain the higher virological success rate in the triple arm. We did not undertake a multivariate analysis given the limited number of failing patients. Indeed, the overall rate of success was high in both arms. Careful analysis of individual cases showed that two of the three cases of virological failure in the two-drug group occurred in non-compliant patients (one had an estimated treatment compliance of 50% during the trial and the other patient had a baseline viral load that was in violation of the inclusion criterion for HIV-1 RNA ,50 copies/mL). Overall, the level of compliance was unexpectedly higher in the three-drug group than in the two-drug group. One hypothesis is that simplification of treatment could have been misinterpreted by the patients of the two-drug group and understood as a reduction of the constraints related to treatment uptake. AEs, lost to follow-up and treatment modifications resulting from patient requests were the main reasons for treatment failure and they were unexpectedly more frequent in the two-drug group than in the three-drug group. Of note, previous HAART at baseline was not different between treatment groups.
Besides the primary objective of this trial, which was to assess the value of a two-drug regimen, we also had the opportunity to evaluate a switch strategy based on the introduction of tenofovir DF plus efavirenz in both treatment groups. The results provide evidence of the benefits of switching to a tenofovir DF plus efavirenz-based regimen on blood lipid parameters (i.e. triglycerides, total cholesterol and HDL cholesterol). In the subgroup of patients (71% of total patients), switching from a thymidine analogue (zidovudine plus lamivudine) to a tenofovir DF-containing regimen was associated with lipid lowering despite normal baseline values (data not shown). Similar changes were previously reported in a controlled trial of tenofovir DF versus stavudine. 14 The clinical benefit of these lipid changes is unknown. One can hypothesize that even patients with normal lipid values at the onset of tenofovir DF-containing treatment may have a decrease in their risk of cardiovascular events. Indeed, some studies have shown, in patients with cardiovascular risk, the substantial cardiovascular benefit of lipid-lowering therapy independently of the initial blood cholesterol level. 15 -17 Other biological measurements also demonstrated benefits of switching to a simplified once-daily regimen containing tenofovir; haemoglobin significantly increased and serum lactic acid significantly decreased. The use of tenofovir DF did not impair the clearance of creatinine, and phosphataemia remained unchanged. This is in keeping with previous long-term studies (up to 3 years). 14, 18 Abdominal SAT assessed by CT scan increased and was accompanied by a decrease in the abdominal VAT/SAT ratio. This suggests that visceral fat increased less than subcutaneous fat. Measurements of total body fat using DEXA analysis showed an increase in peripheral fat not significantly different between the two arms (360 and 280 g in the three-drug and two-drug arms, respectively). In the RAVE study, patients with lipoatrophy treated with a thymidine analogue were switched to abacavir or tenofovir DF. A significant improvement in fat mass measured by DEXA over 48 weeks was also observed in both treatment groups. 19 Our results confirm the benefit of a tenofovir-containing regimen on limb fat mass in patients not selected for lipoatrophy.
One major limitation of this study is its unblinded design. This could explain the significantly higher rate of drug discontinuation in the two-drug group in comparison with that of the three-drug group (18% versus 3%, respectively), which might have been driven by physician and/or patient perception of a suboptimal treatment. Because this trial was designed as a strategic trial, we decided not to use a placebo that would have erased the benefit of regimen simplification. Further studies on induction-maintenance treatment will have to consider this aspect.
Two-drug antiretroviral therapy deserves further evaluation. Interestingly, a recent trial conducted in naive patients (Kalead 1 study) did not evidence non-inferiority of the two-drug group (lopinavir/ritonavir plus tenofovir) versus the three-drug group (lopinavir/ritonavir plus two NRTIs except tenofovir). 20 In conclusion, whereas switching to a tenofovir DF-based regimen improves blood lipid profile even when lipids are within the normal values at baseline and improves limb fat mass over 48 weeks, this study did not demonstrate the non-inferiority of a two-drug regimen (tenofovir DF and efavirenz) compared with a three-drug regimen (tenofovir DF, lamivudine and efavirenz).
